CTLA4 and neoplasm: Yet, an enhanced anti-tumor effect was only seen when anti-CTLA-4 was combined with 50 mg/kg OXi4503, although to some extent with the 25 mg/kg dose; at this lower dose the difference between OXi4503 alone and OXi4503 + anti-CTLA-4 was actually just non-significant (p = 0.06−0.07), but 30% of mice in the combination treatment had complete tumor control.